References
- Yu, D H.; Liu, B L.; Tan, M.; Li, J Z.; Wang, S S.; Hung, M.-C. Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to taxol via MDR-1-independent mechanisms.Oncogene 1996, 13 (6), 1359–1365. [PUBMED], [INFOTRIEVE], [CSA]
- Yu, D H.; Liu, B L.; Jing, T.; Sun, D T.; Price, J E.; , et al. Overexpression of both p185 (c-erbB2) and p170 (MDR-1) renders breast cancer cells highly resistant to taxol.Oncogene 1998, 16 (16), 2087–2094. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yu, D H.; Hung, M C. Role of erbB2 in breast cancer chemosensitivity.Bioessays 2000, 22 (7), 673–680. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Witters, L M.; Santala, S M.; Engle, L.; Chinchilli, V.; Lipton, A. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.Am. J. Clin. Oncol., Cancer Clin. Trials 2003, 26 (1), 50–54. [CSA]
- Yu, D H.; Jing, T.; Liu, B L.; Yao, J.; Tan, M.; McDonnell, T J.; Hung, M.-C. Overexpression of erbB2 blocks taxol-induced apoptosis by upregulation of p21 (cip1), which inhibits p34 (Cdc2) kinase.Mol. Cell 1998, 2 (5), 581–591. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tan, M.; Jing, T.; Lan, K.-H.; Neal, C L.; Li, P.; , et al. Phosphorylation on tyrosine-15 of p34Cdc2 by ErbB2 inhibits p34Cdc2 activation and is involved in resistance to taxol-induced apoptosis.Mol. Cell 2002, 9, 993–1004. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Poznak, C.; Tan, L.; Panageas, K S.; Arroyo, C D.; Hudis, C.; Norton, L.; Seidman, A D. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.J. Clin. Oncol. 2002, 20, 2319–2326. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Baselga, J.; Seidman, A D.; Rosen, P P.; Norton, L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.Oncology (Huntingt.) 1997, 11 (3 Suppl. 2), 43–48. [CSA]
- DiGiovanna, M P.; Carter, D.; Flynn, S D.; Stern, D F. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu -overexpressing invasive breast tumors.Br. J. Cancer 1996, 74, 802–806. [PUBMED], [INFOTRIEVE], [CSA]
- Thor, A D.; Liu, S.; Edgerton, S.; Moore, D.; Kasowitz, K M.; , et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.J. Clin. Oncol. 2000, 18, 3230–3239. [PUBMED], [INFOTRIEVE], [CSA]
- DiGiovanna, M P.; Stern, D F. Activation state specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.Cancer Res. 1995, 55 (9), 1946–1955. [PUBMED], [INFOTRIEVE], [CSA]
- Miller, A B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment.Cancer 1981, 47, 207–214. [PUBMED], [INFOTRIEVE], [CSA]
- Lee, S.; Yang, W T.; Lan, K H.; Sellappan, S.; Klos, K.; , et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in erbB2-overexpressing breast cancer cells.Cancer Res. 2002, 62 (20), 5703–5710. [PUBMED], [INFOTRIEVE], [CSA]
- Slamon, D J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med. 2001, 344, 783–792. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hudelist, G.; Kostler, W J.; Attems, J.; Czerwenka, K.; Muller, R.; , et al. HER-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanism and impact upon the efficacy of trastuzumab-based treatment.Br. J. Cancer 2003, 15 (89), 983–991. [CSA], [CROSSREF]